aug 28, 2016 - FDA announced required class-wide changes to drug labeling to help inform health care providers and patients of the serious risks associated with the combined use of certain opioid medications and a class of central nervous system depressant drugs called benzodiazepines. Among the changes, the FDA is requiring boxed warnings and Medication Guides.
Added to timeline:
Date:
aug 28, 2016
Now
~ 9 years and 9 months ago